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Abstract
Inflammation is a risk factor for morbidity and mortality in the elderly. The neutrophil-to-lymphocyte ratio (NLR) is a marker 
of systemic inflammation that integrates the information of the leukocyte differentials into one variable. We aimed to assess 
whether the NLR is a risk indicator for overall and cause-specific mortality in the general population. We analyzed data 
(2002–2014) from the Rotterdam Study, a long-standing, population-based, prospective cohort study in a community-dwelling 
ageing population. The association between the NLR and time to all-cause mortality was assessed with Cox proportional 
hazard models. We additionally assessed cardiovascular, cancer and other mortality. The multivariable analyses were adjusted 
for age, gender, socio-economic status (SES), smoking status, body mass index, type 2 diabetes, and history of cancer and 
cardiovascular disease (CVD). Data of 8715 individuals were included. The mean age was 65.9 years (SD 10.5) and the 
majority were women (57.1%). The NLR was higher in men, higher age categories, smokers and among individuals with 
lower SES, prevalent diabetes, or a history of cancer or CVD. During the 11.7 years follow-up period, 1641 individuals died. 
Survival among individuals in the 3rd, 4th, and 5th quintile of the NLR was significantly poorer than that of those in the 
1st quintile (P < 0.001). In the multivariable analysis, NLR levels were independently and significantly associated with an 
increased risk of all-cause mortality (HR 1.64; 95% CI 1.44–1.86), cardiovascular mortality (HR 1.92; 95% CI 1.49–2.48), 
and other mortality (HR 1.86; 95% CI 1.54–2.24). No significant association was found for cancer mortality (HR 1.20; 95% 
CI 0.95–1.51). The NLR is a strong and independent risk indicator for mortality in the elderly population. Its clinical value 
needs to be established in further studies.
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Introduction
Inflammation is considered an important risk factor for mor-
bidity and mortality in the elderly. It is still largely unclear 
whether we may speak of a causal relation between inflam-
mation and mortality, or whether the inflammation is a mani-
festation of an underlying illness that causes early death. 
Moreover, the inflammatory markers are known to increase 
with age, therefore an elevation of these markers may also 
be ‘part of the process of ageing’ [1].
C-reactive protein (CRP) has been extensively studied 
as a marker of inflammation and more specifically as a risk 
indicator for cardiovascular, cancer, and all-cause mortality 
[2–5]. Nevertheless, no conclusive evidence has been found 
on its potential causal role in mortality of any cause and 
its clinical use for early identification of patients at risk of 
cardiovascular disease [2, 4, 6]. Furthermore, CRP is likely 
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to be just one of many different elements in the inflamma-
tory pathway.
In an attempt to gain more insight into the relationship 
between inflammation and mortality, also the total leukocyte 
count has been studied. It has previously been shown that 
it is related to cardiovascular, cancer, as well as all-cause 
mortality [7–10]. However, the total leukocyte count encom-
passes several cell types, such as granulocytes, lymphocytes 
and monocytes, which potentially all play a different role 
[11]. Granulocytes, as a whole, or more specifically neutro-
phils, are associated with a negative influence on survival, 
whereas lymphocytes are considered to have protective 
effects on survival [11–13]. While analyzing them together 
would not appreciate the opposite roles they seem to have, 
analyzing them apart would not account for the interaction 
between these subtypes in their association with mortality.
The neutrophil-to-lymphocyte ratio (NLR) is a compos-
ite marker of absolute peripheral neutrophil and lympho-
cyte counts, which can be used to study the effects of both 
simultaneously [14]. It is a well-studied marker for survival 
in patients with cancer and in patients with cardiovascular 
disease [13, 14]. However, it is unknown whether it also is 
predictive of cancer, cardiovascular, or all-cause mortality 
in the general population. To this end we studied the NLR 
and its potential association with overall and cause-specific 
mortality within the context of the Rotterdam Study; a long-
standing, population-based, prospective cohort study among 
a community-dwelling ageing population, with detailed 
information on illness and risk factors for chronic disease. 
We hypothesized that an increased NLR is independently 
associated with mortality in apparently healthy individuals.
Methods
Study design and population
The rationale and design of the Rotterdam Study have previ-
ously been described [15, 16]. Briefly, from 1989 to 1993, 
inhabitants of the suburb of Ommoord in the city of Rot-
terdam, aged 55 years and older, were invited to participate. 
Of 10,275 invited subjects, 7983 participated (78%). A sec-
ond cohort of 3011 persons, also aged 55 years and older, 
(response: 67%) was enrolled in the years 2000 and 2001. 
In 2006, the study was again extended with 3932 persons 
aged 45 years and older (response: 65%). This resulted in an 
overall study population of 14,926 individuals aged 45 years 
and above.
Baseline NLR values were calculated at the earliest study 
center visit at which a leukocyte differential count was 
available: the fourth visit of the first cohort (2002–2004; 
n = 3550), the second visit of the second cohort (2004–2005; 
n = 2468) and the first visit of the third cohort (2006–2008; 
n = 3932).
Individuals who had not proved consent for blood draw 
(N = 1038) were excluded as well as individuals with miss-
ing granulocyte, lymphocyte or platelet counts (N = 197).
The Rotterdam Study has been approved by the insti-
tutional review board (Medical Ethics Committee) of the 
Erasmus Medical Center and by the review board of The 
Netherlands Ministry of Health, Welfare and Sports.
Assessment of the neutrophil‑to‑lymphocyte ratio
Fasting blood samples were collected at the study center 
and full blood count measurements were performed imme-
diately after blood draw. These measurements included 
absolute counts of granulocytes and lymphocytes and were 
performed using the  COULTER® Ac·T diff2™ Hematol-
ogy Analyzer (Beckman Coulter, San Diego, California, 
USA).
The neutrophil-to-lymphocyte ratio (NLR) was calcu-
lated on the basis of absolute peripheral granulocyte (as a 
proxy for the absolute neutrophil count) (N; × 109/Liter) and 
lymphocyte (L;  x109/Liter) blood counts, using the formula: 
NLR = N/L [14].
The NLR was non-normally distributed and therefore log-
transformed prior to performing any of the analyses.
Assessment of other covariates
Data on the following known independent prognostic fac-
tors of mortality were collected at baseline: age, gender, 
socio-economic status (SES; based on education level [high/
intermediate/low]), baseline body mass index (BMI; kg/m2), 
smoking status [never/former/current], prevalent type 2 dia-
betes status (DM; based on a fasting plasma glucose level 
of ≥ 7.0 mmol/L (≥ 126 mg/dL) or non-fasting plasma glu-
cose level of ≥ 11 mmol/L (≥ 200 mg/dL) or use of blood 
glucose medication), history of cancer (based on pathol-
ogy), and lastly, history of cardiovascular disease, including 
transient ischemic attacks (TIA), stroke (CVA), myocardial 
infarction (MI), and coronary revascularization (percutane-
ous transluminal coronary angioplasty or coronary artery 
bypass grafting) [17–19].
High-sensitivity CRP measurements (mg/ml; using a 
particle enhanced immunoturbidimetric assay, Roche Diag-
nostics, Mannheim, Germany) were available in a subgroup 
of the study.
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Assessment of outcome
The main outcome of this study was time to all-cause mor-
tality. Dates of death were obtained through the mortality 
registry of the municipality and the causes of death were 
obtained from general practitioners’ records or hospital dis-
charge letters. The causes of death were coded independently 
by two physicians according to the ICD- 10 and the ICPC-2 
[20, 21].
Statistical analysis
For each participant, follow-up started at the day of inclusion 
and ended at the date of death or end of the study period (1st 
of January 2014), whichever came first.
Participants were divided into five groups based on the 
level of the NLR calculated at baseline. Differences between 
the five groups were assessed with ANOVAs for normally 
distributed continuous variables and χ2-tests for categorical 
variables. Kaplan–Meier plots were calculated for quintiles 
and extreme quantiles of the NLR and compared with Log-
Rank tests.
Proportional hazard models were used to assess the asso-
ciation between the NLR levels at baseline (continuously 
and in quartiles) and time to all-cause mortality. Subse-
quently we assessed the association for cardiovascular and 
cancer mortality, respectively.
For most variables the proportional hazard assump-
tion did not hold. Therefore, follow-up time was divided 
into five strata (< 2 years, 2–4 years, 4–6 years, 6–8 years 
and > 8 years). For example: an individual with an event 
after 5.4 years follow-up, contributed follow-up time to the 
first (2 years), second (2 years) and third stratum (1.4 years). 
The risk of mortality in the last stratum is therefore con-
ditional upon the survival up until that time [22]. We also 
performed a traditional proportional hazard regression, the 
results of which can be interpreted as the averaged risks 
over time [22].
For 5421 individuals we had a second measurement avail-
able, which we included in a multiple measurements analysis 
using a time-varying covariates in a Cox model [23].
All potential confounders, mentioned above, were 
assessed individually and were included in the multivari-
able model when they changed the point estimate by more 
than 10% or were considered as clinically relevant [24]. The 
results are reported as hazard ratios (HR) and 95% confi-
dence intervals (CI). Effect modification was assessed for 
smoking by adding an interaction variable to the model and 
was considered statistically significant at a P value < 0.10. 
We tried to quantify the presence of any unknown and 
therefore unmeasured confounding through calculating the 
E-Value [25].
All statistical analyses were performed using SPSS soft-
ware (Version 21.0) and R (Version 3.1.3); significance was 
accepted for two-sided P-values at < 0.05.
Results
Population characteristics
Data of 8715 participants were included in the analyses (see 
Supplementary Fig. 1). The mean age was 65.9 years; the 
majority were women (4980; 57.1%, see Table 1). During an 
average follow-up period of 7.7 years (maximum follow-up 
period was 11.7 years), a total of 1641 (18.2%) participants 
died, of whom 496 from the consequences of cancer (30.2%) 
and 401 from cardiovascular disease (24.4%). The remaining 
45.4% died from another cause such as: chronic obstructive 
pulmonary disease (COPD), a pneumonia, as a consequence 
of an accidental fall or multi-comorbidity including Parkin-
son’s Disease and Alzheimer’s Disease.
Baseline characteristics for the total population and for 
each quintile of the NLR can be found in Table 1. In sum-
mary, the male gender, a higher age, a lower SES, smok-
ing habit, prevalent diabetes, prior cancer diagnosis, and a 
history of cardiovascular disease were all associated with a 
higher NLR.
Main outcome
The overall survival was poorer for participants in the 
higher quintiles of the NLR than for those in the lowest one 
(Logrank test: P-value < 0.001, see Fig. 1a). Survival of 
participants in the 2nd quintile was not significantly differ-
ent from that of participants in the 1st quintile (reference), 
but for other quintiles it did differ significantly. In a further 
analysis which was restricted to the highest quintile, survival 
for the 1% with the highest NLR levels was worst (Logrank 
test: P-value < 0.001, see Fig. 1b).
Multivariable analysis showed that the NLR was inde-
pendently associated with all-cause mortality, after adjust-
ing for age, gender, SES, BMI, smoking, DM, and history 
of CVD and cancer. The effect of the NLR was not modi-
fied by smoking. On average the risk was increased by 64% 
(HR 1.64; 95% CI 1.44–1.86). The E-values for this analysis 
were 2.17 for the point estimate and 1.89 for the confidence 
intervals, respectively. The observed HR of 1.64 could be 
reduced to 1.00 if there was an unmeasured confounder with 
a risk of 2.17 or above.
In the stratified analysis, the risk was higher in each sub-
sequent quartile, with a significantly higher risk in the fourth 
quartile in comparison to the lowest quartile (HR 1.59, 95% 
CI 1.37–1.86), with a significant trend over the quartiles 
(P-value < 0.001, see Table 2).
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In a sensitivity analysis in which we allowed the NLR 
the change over time for individuals with a second measure-
ment, the averaged risk for all-cause mortality was increased 
with 68% (HR 1.68; 95% CI 1.48–1.90) in the fully adjusted 
model.
The hazard ratio was highest within the first two years 
after baseline, in which individuals with a higher NLR level 
at baseline had a more than twofold risk to die of any cause 
(HR 2.07, 95% CI 1.47–2.90). The hazard ratio gradually 
decreased over time, but the NLR remained. associated 
with an increased risk, albeit non-significantly, of 31% for 
those with a follow-up time of > 8 years (HR 1.31, 95% CI 
0.99–1.73) (see Fig. 2).
Subsequently, we assessed whether the association 
between baseline inflammatory markers and mortality was 
attenuated by CRP. A CRP measurement was available for 
3457 individuals from RS-III. CRP levels were indepen-
dently associated with all-cause mortality, but the asso-
ciation was no longer significant when the NLR was also 
added to the multivariable model. The point estimate of the 
NLR was not attenuated by adding CRP to the model (see 
Table 3).
Sub‑analyses
Additionally, we addressed cause-specific mortality, assess-
ing possible associations between the NLR at baseline and 
risk of cardiovascular-, cancer- and, other mortality. The risk 
for cardiovascular mortality was significantly increased and 
relatively constant over time, with an average HR of 1.92 
(95% CI 1.49–2.48) (Supplementary Fig. 2a). In contrast, no 
significantly increased risk was observed for cancer related 
mortality, with an average HR of 1.20 (95% CI 0.95–1.51) 
(Supplementary Fig. 2B). For other mortality the average 
risk was significantly increased by 86% (HR 1.86; 95% CI 
1.54–2.24). It was highest in the first 2 years with a HR of 
4.28 (95% CI 2.44–7.51) and decreased over time to a 31% 
higher, albeit statistically non-significant, risk for individuals 
with a follow-up time > 8 years (HR 1.31, 95% CI 0.90–1.91) 
(Supplementary Fig. 2C).
Discussion
Previous studies have shown that the NLR is a prognostic 
marker for mortality in patients with cardiovascular dis-
ease and cancer [13, 14]. We hypothesized that the NLR 
was independently associated with mortality in apparently 
healthy individuals. To our knowledge, this is the first study 
confirming this hypothesis of an independent relationship 
Fig. 1  a Kaplan–Meier curves for all-cause mortality for each quintile 
of the NLR (P-value < 0.001). b Kaplan–Meier curves for all-cause 
mortality for the highest quintile of the NLR (P-value < 0.001)
Table 2  Cox proportional 
hazard regression for the 
association of the NLR and all-
cause mortality
Adjusted for: gender, age in years, SES (socio-economics status: high/intermediate/low), smoking status 
(current/former/never), BMI (body mass index: kg/m2), DM (type 2 diabetes mellitus status), history of 
cancer and history of cardiovascular disease. P-value for trend over quartiles < 0.001
Events/cohort NLR HR Lower 95% CI Upper 95% CI
1551/8352 Logtransformed 1.64 1.44 1.86
226/2107 Q1 Reference – –
274/2073 Q2 1.05 0.88 1.25
374/2082 Q3 1.13 0.96 1.33
677/2090 Q4 1.59 1.37 1.86
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between the NLR and early mortality in the general 
population.
Multiple studies have investigated the association 
between the WBC count or the leukocyte differentials and 
all-cause mortality, but none studied individual cell types 
in relationship to each other. The NLR integrates the infor-
mation obtained from the leukocyte differentials and pro-
vides the opportunity to simultaneously study the associa-
tion between neutrophils and all-cause mortality and that 
between lymphocytes and mortality.
Our results are largely in agreement with the results pre-
viously found for the association between the WBC count 
and overall mortality. The WBC count has been consistently 
associated with both total and cardiovascular mortality. In 
our study, the association of the NLR with cancer mortality 
was much weaker and non-significant. Although this might 
seem counterintuitive because of the prognostic role of the 
NLR in people with cancer, it is not unexpected as cancer 
mortality largely depends on available therapeutic options 
and cancer type. Again this is consistent with literature on 
the WBC count and cancer mortality in the general popula-
tion [26, 27].
Fig. 2  Risk of NLR-related all-cause mortality over time. Adjusted 
for: sub-cohort, gender, age (in years), socio-economic status (high/
intermediate/low), smoking status (current/former/never), BMI (body 
mass index, kg/m2), prevalent type 2 diabetes mellitus, history of car-
diovascular disease and history of cancer. Risk for each time stratum 
were for: baseline–2 years (HR 2.07, 95% CI 1.47–2.90), 2–4 years 
(HR 1.72, 95% CI 1.30–2.28), 4–6  years (HR 1.53, 95% CI 1.18–
2.00), 6–8  years (HR 1.84, 95% CI 1.40–2.42) and > 8  years (HR 
1.31, 95% CI 0.99–1.73)
Table 3  Cox proportional hazard regression for the association of the NLR and all-cause mortality, additionally adjusted for CRP, in a sub-
population of the cohort
For 3457 individuals from RS-III we had a CRP measurement available, we added CRP to the model to see whether the association between the 
NLR and the all-cause mortality was attenuated. In RS-III in total 129 individuals died. Proportional hazard assumptions were tested separately 
in this sub-population and upheld for all variables. History of CVD was neither a significant predictor nor a confounder in this subpopulation and 
was therefore not included in the model
HR hazard ratio, SES socio-economic status, BMI body mass index, NLR neutrophil-to-lymphocyte ratio, CRP C-reactive protein, CVD cardio-
vascular disease
Clinical vari-
able
Main model + NLR Main model + CRP Main model + NLR + CRP
HR Lower 95% 
CI
Upper 95% 
CI
HR Lower 95% 
CI
Upper 95% 
CI
HR Lower 95% 
CI
Upper 95% CI
Female 0.75 0.52 1.08 0.72 0.50 1.04 0.78 0.54 1.13
Age (in years) 1.09 1.07 1.11 1.10 1.08 1.12 1.09 1.07 1.11
SES
 High Reference Reference Reference
 Intermediate 1.27 0.76 2.12 1.21 0.73 2.03 1.21 0.72 2.02
 Low 1.74 1.03 2.93 1.57 0.93 2.66 1.56 0.92 2.64
Smoking
 Never Reference Reference Reference
 Former 2.04 1.20 3.49 1.96 1.14 3.36 1.94 1.29 3.32
 Current 3.38 1.93 5.93 3.47 1.97 6.11 3.35 1.90 5.91
History 
cancer
2.56 1.57 4.17 2.60 1.59 4.25 2.59 1.58 4.23
DM 1.37 0.83 2.26 1.44 0.87 2.39 1.44 0.87 2.38
BMI (in kg/
m2)
0.98 0.94 1.02 0.98 0.94 1.02 0.98 0.94 1.02
NLR 2.04 1.31 3.20 – – – 1.92 1.19 3.10
CRP (in mg/
ml)
– – – 1.20 1.02 1.42 1.12 0.94 1.33
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The effects are controlled for important confounders 
such as smoking and a higher BMI or comorbidities, such 
as a history of cardiovascular disease, diabetes or a history 
of cancer. It is known that the leukocyte and neutrophil 
counts are also higher in smokers [7, 28]. We indeed found 
that smoking is an important confounder. The association 
remains robust, however, after adjustment for this factor, 
which implies that only part of the association between the 
NLR and mortality is explained by smoking. Moreover, 
there was no effect modification of smoking, meaning that 
the magnitude of the association was not different in smok-
ers compared to non-smokers. Furthermore, the NLR proved 
the strongest risk indicator when both CRP and the NLR 
were included in the model. This means that the association 
was independent from the relationship between CRP and 
mortality, which suggests that a potential inflammatory path-
way that is explained by CRP, is different from the pathway 
than the one represented by the NLR.
We tried to quantify the presence of any unknown and 
therefore unmeasured confounding through calculating 
the E-Value [25]. Although any residual confounding can-
not be completely ruled out, we found that any unknown 
confounder would have to have a risk of 2.17 or above to 
explain the observed effect. Considering the large number 
of confounders we have adjusted for, we believe it is unlikely 
that the effects in this study can be explained by such strong 
residual confounding.
Overall, our findings seem to confirm that there is an 
independent relationship between inflammation and mortal-
ity. What the nature of this association is, remains uncertain. 
Although the relationship might be etiological, it may also 
be that the NLR is a proxy measure of the ageing process or 
rather a manifestation of an underlying disease.
Consistent with this latter hypothesis, we found that the 
NLR-related risk of mortality was highest for the first two 
years of follow-up and decreased over time. This is explained 
by the effects seen for other mortality (see Supplementary 
Fig. 2C) and may be a result of a depletion of individuals 
with an underlying illness or poor health status. However we 
controlled for history of cancer and cardiovascular disease 
and even when the first 8 years of follow-up are excluded, 
the association still persists, making underlying disease a 
less likely explanation.
Another explanation may be that of a causal association. 
For instance, it is known that neutrophils infiltrate athero-
sclerotic plaques and may play a role in the rupture, resulting 
in a cardiovascular incident [29.] However, this would mean 
there is an intermediate between the NLR and mortality and 
that neutrophils play no role in the actual process of dying.
The last explanation would be that the immune system 
gets damaged as part of the ageing process and that the NLR 
is a proxy marker for this biological phenomenon.
Strengths and limitations
A large population-based and prospective cohort study such 
as the Rotterdam Study, with a long follow-up period and 
detailed information on prevalent disease and important 
risk factors, is the design of choice for studying associa-
tions between blood levels of inflammatory markers and all-
cause mortality.
The NLR is derived from the leukocyte differentials, 
which is a stable, well-standardized and inexpensive meas-
urement that reflects systemic inflammation. Still, cut-off 
values to stratify patients into currently unidentified risk 
groups are still lacking. These cut-off values are necessary 
to evaluate the clinical utility of the NLR.
Another limitation of this study is the fact that the total 
granulocyte count served as a proxy for the total neutrophil 
count. We assume, however, that this has had little impact on 
the results as neutrophils are by far the most abundant type 
of granulocytes [30]. Any resulting misclassification could 
have led to an overestimation, but it has been conclusively 
shown that the associations for granulocytes and neutrophils 
have the same direction and the same effect size [12]. We 
believe the obtained effect measures are a fair representation 
of the true effect.
In conclusion, we have demonstrated that the NLR is 
independently associated with all-cause mortality in the 
elderly population, after adjustment for traditional risk fac-
tors. Its potential value in clinical practice needs to be estab-
lished in further studies.
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